Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Although the FDA revoked metastatic breast cancer (MBC) from bevacizumab (BEV) indication in 2011, BEV combined with paclitaxel has been written in the breast cancer NCCN guidelines. This systematic assessment was performed to evaluate the efficacy and safety of BEV + chemotherapy (CHE) for managing...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qin, Yan, Han, Zhao, Pengfei, Yang, Yifan, Cao, Bangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621503/
https://www.ncbi.nlm.nih.gov/pubmed/26503902
http://dx.doi.org/10.1038/srep15746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621503/
https://www.ncbi.nlm.nih.gov/pubmed/26503902
http://dx.doi.org/10.1038/srep15746

Ejemplares similares